Expression of Phosphodiesterase 4D (PDE4D) Is Regulated by Both the Cyclic AMP-dependent Protein Kinase and Mitogen-activated Protein Kinase Signaling Pathways

Multiple families of cyclic nucleotide phosphodiesterases (PDE) have been described, and the regulated expression of these genes in cells is complex. Although cAMP is known to control the expression of certain PDE in cells, presumably reflecting a system of feedback on cAMP signaling, relatively little is known about the influence of non-cAMP signaling systems on PDE expression. In this study, we describe a novel mechanism by which activators of the protein kinase C (PKC)-Raf-MEK-ERK cascade regulate phosphodiesterase 4D (PDE4D) expression in vascular smooth muscle cells (VSMC) and assess the functional consequences of this effect. Whereas a prolonged elevation of cAMP in VSMC resulted in a protein kinase A (PKA)-dependent induction of expression of two PDE4D variants (PDE4D1 and PDE4D2), simultaneous activation of both the cAMP-PKA and PKC-Raf-MEK-ERK signaling cascades blunted this cAMP-mediated increase in PDE4D expression. By using biochemical, molecular biological, and pharmacological approaches, we demonstrate that this PDE4D-selective effect of activators of the PKC-Raf-MEK-ERK cascade was mediated through a mechanism involving altered PDE4D mRNA stability and markedly attenuated the cAMP-mediated desensitization that results from prolonged activation of the cAMP signaling system in cells. The data are presented in the context of activators of the PKC-Raf-MEK-ERK cascade having both short and long term effects on PDE4D activity and expression in cells that may influence cAMP signaling.

[1]  M. Leroy,et al.  Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors. , 2000, The Journal of pharmacology and experimental therapeutics.

[2]  M. Movsesian.  Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. , 1999, Journal of the American College of Cardiology.

[3]  J. Beavo,et al.  Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Maurice,et al.  Phosphorylation-mediated Activation and Translocation of the Cyclic AMP-specific Phosphodiesterase PDE4D3 by Cyclic AMP-dependent Protein Kinase and Mitogen-activated Protein Kinases , 1999, The Journal of Biological Chemistry.

[5]  G. Baillie,et al.  The MAP kinase ERK2 inhibits the cyclic AMP‐specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579 , 1999, The EMBO journal.

[6]  H. Liu,et al.  Expression of cyclic GMP‐inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP , 1998, British journal of pharmacology.

[7]  J. Polson,et al.  Effect of CI-930 [3-(2H)-pyridazinone-4,5-dihydro-6-[4-(1H-imidazolyl) phenyl]-5-methyl-monohydrochloride] and rolipram on human coronary artery smooth muscle cell proliferation. , 1998, Biochemical pharmacology.

[8]  I. Adcock,et al.  Induction of Phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in Human Peripheral Blood T-lymphocytes by 8-Bromo-cAMP and Gs-coupled Receptor Agonists , 1998, The Journal of Biological Chemistry.

[9]  M. Houslay,et al.  cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. , 1998, The Biochemical journal.

[10]  J. Beavo,et al.  Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases* , 1998, The Journal of Biological Chemistry.

[11]  J. Cheng,et al.  Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. , 1998, Biochemical and biophysical research communications.

[12]  D. Maurice,et al.  Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. , 1998, Circulation research.

[13]  E. Krebs,et al.  Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. , 1997, The Journal of clinical investigation.

[14]  M. Houslay,et al.  Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. , 1997, Journal of molecular and cellular cardiology.

[15]  H. Liu,et al.  Cyclic AMP‐mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity , 1997, British journal of pharmacology.

[16]  E. Degerman,et al.  Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3)* , 1997, The Journal of Biological Chemistry.

[17]  D. Kassel,et al.  Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase. , 1996, The Biochemical journal.

[18]  M. Mclaughlin,et al.  Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. , 1996, The Journal of pharmacology and experimental therapeutics.

[19]  M. Conti,et al.  Phosphorylation and Activation of a cAMP-specific Phosphodiesterase by the cAMP-dependent Protein Kinase , 1995, The Journal of Biological Chemistry.

[20]  H. Sarau,et al.  Salbutamol Up-regulates PDE4 Activity and Induces a Heterologous Desensitization of U937 Cells to Prostaglandin E2 , 1995, The Journal of Biological Chemistry.

[21]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[22]  M. Conti,et al.  Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. , 1995, Molecular pharmacology.

[23]  M. Houslay,et al.  Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. , 1995, The Biochemical journal.

[24]  J. Lenhard,et al.  Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. , 1995, Molecular pharmacology.

[25]  M. Conti,et al.  The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. , 1994, The Journal of biological chemistry.

[26]  R. M. Lee,et al.  Measurement of both cyclic [3H]AMP and cyclic [3H]GMP in cultured vascular smooth muscle cells labeled with [3H]hypoxanthine: use in studies of cardiovascular drugs. , 1993, Analytical biochemistry.

[27]  V. Manganiello,et al.  Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. , 1993, Biochemical and biophysical research communications.

[28]  T. Torphy,et al.  Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. , 1992, The Journal of pharmacology and experimental therapeutics.

[29]  G. Hassall,et al.  Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. , 1992, Biochemical pharmacology.

[30]  E. Degerman,et al.  Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. , 1992, Biochimica et biophysica acta.

[31]  C. Lugnier,et al.  Endothelium‐dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors , 1991, British journal of pharmacology.

[32]  V. Manganiello,et al.  Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. , 1991, The Journal of clinical investigation.

[33]  D. Crankshaw,et al.  Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. , 1991, European journal of pharmacology.

[34]  R. Haslam,et al.  Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. , 1990, European journal of pharmacology.

[35]  J. Beavo,et al.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. , 1990, Trends in pharmacological sciences.

[36]  M. Conti,et al.  The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Lugnier,et al.  Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. , 1987, Biochemical pharmacology.

[38]  C. Lugnier,et al.  Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. , 1986, Biochemical pharmacology.

[39]  D. B. Evans,et al.  Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. , 1986, Biochemical pharmacology.

[40]  D. Juilfs,et al.  Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). , 1999, Reviews of physiology, biochemistry and pharmacology.

[41]  M. Conti,et al.  The molecular biology of cyclic nucleotide phosphodiesterases. , 1999, Progress in nucleic acid research and molecular biology.

[42]  M. Houslay,et al.  The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. , 1998, Advances in pharmacology.

[43]  M. Houslay,et al.  Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase. , 1997, The Biochemical journal.

[44]  M. Houslay,et al.  Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. , 1997, The Biochemical journal.

[45]  J. Polson,et al.  Cyclic nucleotide phosphodiesterases and vascular smooth muscle. , 1996, Annual review of pharmacology and toxicology.

[46]  A. Hatzelmann,et al.  10 – Enzymatic and Functional Aspects of Dual-selective PDE3/4 Inhibitors , 1996 .